TY - JOUR
T1 - Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people with HIV with hyporesponse after primary vaccination
AU - Jongkees, Marlou J
AU - Geers, Daryl
AU - Hensley, Kathryn S
AU - Huisman, Wesley
AU - GeurtsvanKessel, Corine H
AU - Bogers, Susanne
AU - Gommers, Lennert
AU - Papageorgiou, Grigorios
AU - Jochems, Simon P
AU - den Hollander, Jan G
AU - Schippers, Emile F
AU - Ammerlaan, Heidi S M
AU - Bierman, Wouter F W
AU - van der Valk, Marc
AU - Berrevoets, Marvin A H
AU - Soetekouw, Robert
AU - Langebeek, Nienke
AU - Bruns, Anke H W
AU - Leyten, Eliane M S
AU - Sigaloff, Kim C E
AU - van Vonderen, Marit G A
AU - Delsing, Corine E
AU - Branger, Judith
AU - Katsikis, Peter D
AU - Mueller, Yvonne M
AU - de Vries, Rory D
AU - Rijnders, Bart J A
AU - Brinkman, Kees
AU - Rokx, Casper
AU - Roukens, Anna H E
N1 - Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - BACKGROUND: The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponders. METHODS: The primary end point was the increase in antibodies 28 days after additional mRNA-1273 vaccination. Secondary end points included neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity. RESULTS: Of the 66 participants, 40 previously received 2 doses ChAdOx1-S, 22 received 2 doses BNT162b2, and 4 received a single dose Ad26.COV2.S. The median age was 63 years (interquartile range [IQR], 60-66), 86% were male, and median CD4+ T-cell count was 650/μL (IQR, 423-941). The mean S1-specific antibody level increased from 35 binding antibody units (BAU)/mL (95% confidence interval [CI], 24-46) to 4317 BAU/mL (95% CI, 3275-5360) (P < .0001). Of all participants, 97% showed an adequate response and the 45 antibody-negative participants all seroconverted. A significant increase in the proportion of PWH with ancestral S-specific CD4+ T cells (P = .04) and S-specific B cells (P = .02) was observed. CONCLUSIONS: An additional mRNA-1273 vaccination induced a robust serological response in 97% of PWH with a hyporesponse after primary vaccination. Clinical Trials Registration. EUCTR2021-001054-57-N.
AB - BACKGROUND: The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponders. METHODS: The primary end point was the increase in antibodies 28 days after additional mRNA-1273 vaccination. Secondary end points included neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity. RESULTS: Of the 66 participants, 40 previously received 2 doses ChAdOx1-S, 22 received 2 doses BNT162b2, and 4 received a single dose Ad26.COV2.S. The median age was 63 years (interquartile range [IQR], 60-66), 86% were male, and median CD4+ T-cell count was 650/μL (IQR, 423-941). The mean S1-specific antibody level increased from 35 binding antibody units (BAU)/mL (95% confidence interval [CI], 24-46) to 4317 BAU/mL (95% CI, 3275-5360) (P < .0001). Of all participants, 97% showed an adequate response and the 45 antibody-negative participants all seroconverted. A significant increase in the proportion of PWH with ancestral S-specific CD4+ T cells (P = .04) and S-specific B cells (P = .02) was observed. CONCLUSIONS: An additional mRNA-1273 vaccination induced a robust serological response in 97% of PWH with a hyporesponse after primary vaccination. Clinical Trials Registration. EUCTR2021-001054-57-N.
UR - http://www.scopus.com/inward/record.url?scp=85149183343&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiac451
DO - 10.1093/infdis/jiac451
M3 - Article
C2 - 36402141
SN - 0022-1899
VL - 227
SP - 651
EP - 662
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 5
ER -
